Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 805 results for "alexion pharmaceuticals"

Potential Alexion Pharmaceuticals (ALXN) Trade Has 5.60% Downs...

MarketIntelligenceCenter.comaEUR(TM)s patented option-trade picking algorithm found two trade ideas on Alexion Pharmaceuticals Inc (http://www.marketintelligencecenter.com/symbol/ALXN"ALXN) today after it traded between between $164.58 and $168.48 ... Individual.com, 15 hours ago

56 images for alexion pharmaceuticals

American Banking News, 3 weeks ago
Wall Street Pit, 2 weeks ago
Wall Street Pit, 2 weeks ago
Wall Street Pit, 2 weeks ago
Wall Street Pit, 2 weeks ago
Wall Street Pit, 2 weeks ago
Jutia Group, 3 weeks ago
State Of The Markets.com, 2 weeks ago
Jutia Group, 1 month ago
Forbes.com, 2 weeks ago

Growth Prospects Still Solid At Alexion Pharmaceuticals

Alexion Pharmaceuticals (ALXN) may be a one-hit wonder, but it's a very lucrative one. Despite a small market for its only marketed drug, Soliris, Alexion generated $1.55 billion in sales in 2013, up 37% from 2012. This year, sales are seen rising ...
 Town Hall13 hours ago
[x]  

Alexion Pharmaceuticals (ALXN) Showing Bullish Technicals With Resistance At $170.86

The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Alexion Pharmaceuticals Inc (http://www.marketintelligencecenter.com/symbol/ALXN"ALXN) that should provide a 4.20% return in just 54 ...
 Individual.com1 day ago Alexion Pharmaceuticals (ALXN) Trading Near $155.14 Support Level  PredictWallStreet5 days ago
[x]  

Riassunto: I pazienti pediatrici affetti da ipofosfatasia trattati col farmaco sperimentale asfotase alfa hanno mostrato miglioramenti nella crescita e nelle funzionalità fisiche

DUBLINO, Irlanda--( BUSINESS WIRE )--Alexion Pharmaceuticals ha oggi annunciato che alcuni ricercatori hanno presentato i dati di estensioni dello studio di fase 2 in aperto su asfotase alfa, una terapia enzimatico-sostitutiva (ERT) ...
 Business Wire1 week ago 5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential  24/7 Wall St5 days ago Anhaltende Verbesserungen der körperlichen Funktion und des Wachstums bei pädiatrischen Patienten mit Hypophosphatasie nach der Therapie mit dem Prüfpräparat Asfotase Alfa  Business Wire1 week ago Les patients pédiatriques atteints d'hypophosphatasie et recevant de l'Asfotase Alfa expérimentale ont constaté des améliorations constantes de la croissance et de la fonction physique  Business Wire1 week ago
[x]  

Buyers Accumulate Shares of Alexion Pharmaceuticals, Up 4.0%

Alexion Pharmaceuticals (NASDAQ:ALXN) is one of today's biggest movers, up 4.0% to $165.01. The S&P is currently trading 0.4% higher to 1,990 and the Dow Jones Industrial Average is trading 0.5% higher
 Individual.com6 days ago Stock Investors Sell Off Shares of Alexion Pharmaceuticals, Down 2.9%  Individual.com2 weeks ago Alexion Pharmaceuticals Shares Sinking Lower, Down 1.5%  Individual.com2 weeks ago Alexion Pharmaceuticals Makes a Move: Do...  Financial News Network online3 weeks ago

Resumen: Los pacientes pediátricos con hipofosfatasia que han recibido asfotasa alfa experimental han registrado mejoras constantes en la función física y crecimiento

DUBLÍN, Irlanda--( BUSINESS WIRE )--Alexion Pharmaceuticals ha comunicado que los investigadores han presentados datos de las fases de prolongación abiertas de dos estudios de fase 2 de la asfotasa alfa, un tratamiento en fase de ...
 Business Wire1 week ago Resumen: Se ha observado una mejora en la supervivencia de los pacientes pediátricos con hipofosfatasia grave (HPP) que han sido tratados con el fármaco en fase de investigación Asfotase Alfa durante cinco años  Business Wire2 weeks ago

Alexion announces encouraging data from hypophosphatasia analysis

Alexion Pharmaceuticals, Inc. has announced encouraging data from an integrated analysis of survival from two open-label, Phase II studies of asfotase alfa in pediatric patients with hypophosphatasia, or HPP, compared with data from a retrospective ...
 Individual.com1 week ago Alexion report new data from two open-label, Phase II studies of asfotase alfa in pediatric patients  Pharmaceutical Business Review1 week ago

Execs move up at Alexion

News Editor Alexion Pharmaceuticals (NASDAQ:ALXN) promotes key executives. EVP and Chief Commercial Officer David Hallal promoted to COO. SVP and Chief HR Officer Clare Carmichael promoted to EVP and CHRO. SVP and General Counsel John ...
 Seeking Alpha1 week ago

Alexion Names David Hallal COO - Quick Facts

Alexion Pharmaceuticals, Inc. (ALXN: Quote), whose durg Soliris treats two rare diseases, Wednesday said it is promoting David Hallal to the newly created position of chief operating officer. Hallal, who joined the company in 2006, was previously ...
 RTTNews.com2 weeks ago

ALEXION PHARMACEUTICALS INC FILES (8-K) Disclosing Change in Directors or Principal Officers, Financial Statements and Exhibits

(Edgar Glimpses Via Acquire Media NewsEdge) Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Mr. David Hallal has been named Chief ...
 TMC Net2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less